Compare KEQU & TVGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KEQU | TVGN |
|---|---|---|
| Founded | 1906 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Blank Checks |
| Sector | Industrials | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 106.3M | 21.3M |
| IPO Year | 1995 | 2021 |
| Metric | KEQU | TVGN |
|---|---|---|
| Price | $34.88 | $7.81 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 2.1K | ★ 6.5K |
| Earning Date | 03-11-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.58 | N/A |
| Revenue | ★ $138,558,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $62.26 | ★ N/A |
| Revenue Growth | ★ 7.72 | N/A |
| 52 Week Low | $32.00 | $0.14 |
| 52 Week High | $46.57 | $12.03 |
| Indicator | KEQU | TVGN |
|---|---|---|
| Relative Strength Index (RSI) | 42.12 | 67.37 |
| Support Level | $32.99 | $6.22 |
| Resistance Level | $35.35 | $7.90 |
| Average True Range (ATR) | 1.21 | 0.41 |
| MACD | -0.11 | 0.04 |
| Stochastic Oscillator | 53.13 | 88.98 |
Kewaunee Scientific Corp is engaged in the design, manufacture, and installation of laboratory, healthcare, and technical furniture and infrastructure products. Its products include steel and wood casework, fume hoods, adaptable modular systems, movable workstations, stand-alone benches, biological safety cabinets, epoxy resin work surfaces, and sinks. The company operates through two reportable segments: Lab Products Group (LPG), which designs, manufactures, and installs scientific and technical furniture, including steel and wood laboratory cabinetry, fume hoods, flexible systems, work surfaces, workstations, workbenches, and computer enclosures, and the International segment.
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The first clinical product of ExacTcell, TVGN 489, is initially being developed to fill a critical gap in COVID-19 therapeutics for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of chronic, lingering symptoms of the disease (Long COVID). Viruses, including COVID-19, hijack cellular machinery to transform infected cells into virus production plants.